A key unresolved challenge for developing an effective HIV-1 vaccine is the discovery of strategies to elicit immune responses that are able to cross-protect against a significant fraction of the diverse viruses that are circulating worldwide. Here, we summarize some of the immunological implications of HIV-1 diversity, and outline the rationale behind several polyvalent vaccine design strategies that are currently under evaluation. Vaccine-elicited T-cell responses, which contribute to the control of HIV-1 in natural infections, are currently being considered in both prevention and treatment settings. Approaches now in preclinical and human trials include full proteins in novel vectors, concatenated conserved protein regions, and polyvalent strategies that improve coverage of epitope diversity and enhance the cross-reactivity of responses.
Within each of the more than 70 million people who have been infected with HIV-1 since the beginning of the pandemic, 3 an extraordinary evolutionary process has played out. High baseline rates of HIV-1 mutation 6 and replication 7 lay a foundation of viral diversity, and this combined with continuous immune-driven selection generates a complex and unique viral quasispecies in each infected person. [8] [9] [10] [11] [12] An extensive range of mutations and combinations of mutations, even within single epitopes, can be explored by the virus in response to immune pressures, 8, 9, 13 and the delicate balance of immune escape and replicative fitness shifts over time as other mutations, sometimes compensatory, come into play.
14 Successful ART constrains this dynamic, although the extent to which the virus continues to replicate during ART is still not fully resolved. 15 Unless ART is given immediately after infection, HIV-1 will have established a highly complex population of variants by the time therapy is initiated, including a latent reservoir that persists despite therapy and reactivates when ART is discontinued or when drug-resistance develops. 16 Thus, immunologically relevant mutations accrue in every infected individual, creating a unique and highly complex mixture of variants within each host. When an infected person passes the virus to another individual, one or more of these variants will establish a new infection in the next individual in the chain, ultimately giving rise to a highly diverse global virus population. A successful vaccine must counter this diversity. 17, 18 The term "wildtype" virus, which traditionally refers to the dominant form in a viral population, makes little sense in the context of HIV-1, yet the term is often used. Population-based viral consensus sequences are sometimes referred to as wildtype, but even within a genetic clade, they are quite distant from any natural isolate.
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Each of the 35 million HIV-1 infections in the world today is comprised of numberous coexisting variants. Thus, we are confronted with 35 million related, but distinct "wildtypes", each of which embodies a complex viral quasispecies. Given the very high cost of vaccine development, it is generally considered prohibitive to include more than two or possibly three, antigens in a polyvalent vaccine. Two or three against 35 million is a daunting ratio, and it is no wonder that an effective vaccine still eludes us! As a result, much current effort is focused on the design and selection of sets of vaccine antigens that may ultimately be able to effectively counter the entirety of HIV-1 diversity.
This review will discuss vaccine strategies that utilize sets of proteins for use as polyvalent immunogens. These strategies include bioinformatic designs of artificial proteins that can improve epitope coverage, 19, 20 as well as lineage-based designs intended to recreate the immunological events that resulted in broadly cross-reactive neutralizing antibodies during natural infection. 21 These strategies begin to address the challenge of devising vaccines that can elicit responses capable of protecting against a significant fraction of the spectrum of highly diverse circulating HIV-1 strains.
| VACCINE APPROACHES TO CONTEND WITH HIV-1 DIVERSITY
The highly diverse set of viruses that make up most of the global HIV-1 epidemic are classified into four groups (M, N, O, and P) based on their phylogenetic relationships and zoonotic origins. Group M, the "Main" group of HIV-1, is further subdivided into several distinct clades (or subtypes), which have been labeled A-K. 22 In addition many inter-subtype recombinants are circulating, some of which establish important epidemic lineages. 23 A number of regional epidemics are dominated by a single clade-the B clade in North America, and the C clade in Southern Africa and India-but in most places in the world different clades and recombinant forms co-circulate. 22 The Los Alamos HIV database provides an interactive map showing the global distribution of different clades and circulating recombinant forms, as they have been sampled and sequenced (http://www.hiv.lanl.gov/components/sequence/HIV/geo/geo.comp).
An early vaccine approach to cover HIV-1 diversity was to include one virus sampled from each of several major clades. 24 Unfortunately, the results of the human efficacy phase 2b trial HVTN 505, which tested a combination of three envelope (Env) immunogens from different clades as a vaccine, were disappointing. 25 The HVTN 505
vaccine included a multivalent (six plasmid) DNA prime, each plasmid expressing either a clade B gag, pol or nef or a clade A, B or C env gene, followed by a boost with four recombinant adenovirus (rAd5) vectors expressing either a clade B Gag/Pol fusion protein, or clade A, B or C
Envs. The vaccine was tested in a population at increased risk of infection in the United States, a predominantly B clade HIV-1 epidemic.
Hence, the vaccine-induced Gag-and Pol-specific T-cell responses had to act only in a within-clade context, while the polyvalent Env combination was designed to counter a more diverse set of viruses. This approach did not reduce either the rate of acquisition or set point viral load of new HIV-1 infections.
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One potential way to improve the breadth of vaccine responses relative to simply using a natural variant is to minimize rare amino acids at positions that might focus the immune system on epitopes that yield type-specific responses. A recently discovered class of rare mutations that can result in potent, but type-specific, neutralizing antibody responses are unusual gaps in the Env glycan shield. 26 For example, the loss of a highly conserved glycosylation site at position 241 (based on HXB2 numbering) in the BG505 Env resulted in such a "glycan hole".
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When the BG505 glycoprotein was delivered in a vaccine as a soluble, near-native SOSIP trimer, the resulting autologous antibody responses specifically targeted this rare glycan hole.
There are several approaches that can be used to avoid targeting rare epitope variants. One approach involves Mosaic or Epigraph vaccines, which are artificial proteins that resemble natural proteins, but are designed in silico to maximize inclusion of the most common forms of linear epitopes. 19, 20 By design, Mosaic vaccines disfavor inclusion of very rare amino acids at any given position. In addition, they disfavor 
| T-CELL VACCINE DESIGN STRATEGIES
The HIV-1 T-cell vaccine field has made significant advances since the first T-cell based vaccine failed to prevent infection or improve viral control in vaccinated individuals who became infected. 29, 30 The Ad5 vectored vaccines used in these trials may even have enhanced HIV-1 infection rates. 29, 30 Despite these early setbacks, there are several reasons for renewed optimism regarding the value of T-cell approaches, in both preventative and therapeutic settings. These include the use of cytomegalovirus (CMV) vectors, the use of polyvalent Mosaic antigens, and the design of immunogens specifically based on highly conserved regions. Each of these approaches may be successful when used alone, but may have even greater potential when used in combination.
| CMV vectors
A novel CMV vector developed by Louis Picker et al. [31] [32] [33] has elicited unusual and protective T-cell responses in rhesus macaques. Over 50% of SIVmac infections were effectively cleared in animals that
The diversity of HIV-1 Env and Gag considered in terms of epitope-length fragments (9-mers). The left-hand panels (A and C) summarize the frequency of each unique 9-mer in the global 2015 HIV M group alignments curated at the Los Alamos database (http://www. hiv.lanl.gov/content/sequence/NEWALIGN/align.html, 08/31/2015). Note the log scale on the y-axis. While the overall distribution is captured here, the very high numbers of completely unique epitopes that was brought out in the main text are difficult to discern, as the green line corresponding to number of distinct 9-mers that are only repeated once is very thin and on the extreme left. There are, precisely, 89 957 9-mers only found once of 136 828 unique 9-mers found in 4500 Gag sequences, and 556 401 9-mers found only once out of 719 578 unique 9-mers among 4600 Env sequences. The right-hand panels (B and D) show the coverage, as number of perfect 9-mer matches, that can be obtained with a 3-valent antigen vaccine. The coverage distribution shown in grey is based on 1000 trials, each a random selection of three natural strains from the data set, as a putative polyvalent immunogen. The best 9-mer coverage possible is indicated by a red line, and the median value for the set is noted. The coverage achieved by a 3-valent Epigraph vaccine is indicated by the blue line, and is expected to be comparable to a Mosaic design. The new epigraph tool suite was used to create this figure 
| Computational design of polyvalent T-cell vaccines
A second important advance for promising T-cell vaccine strategies is the finding that polyvalent HIV-1 Mosaic antigens result in significantly greater breadth and potency of vaccine-elicited T-cell responses than do natural proteins in NHP studies. [34] [35] [36] [37] [38] [39] the appropriate conformational shift when bound to CD4, 36 and so are assumed to form native-like proteins. However, the SIV mosaics were not similarly evaluated. Epigraphs. 20 Epigraphs use a computationally highly efficient graph theory approach to solve essentially the same design problem as Mosaics, thereby reducing computer run times from hours to seconds.
Thus, the increased computational efficiency allows the exploration of subtle vaccine-design problems that were previously intractable using the Mosaic code. These include exploring the coverage impact of excluding rare epitopes from the vaccine antigens, and exploring coverage optimization including imperfect matches between potential epitopes as well as perfect matches. In addition, Epigraphs enable a strategy to develop a set of antigens for a tailored approach in the context of therapeutic vaccines. 20 In this scenario, an infected subject's viruses could be sequenced, and those sequences used to inform the vaccine selection. As a new vaccine could not feasibly be produced for every subject, a reasonable number of immunogens could be produced (eg, six), and the two best matches with the subject's HIV-1 sequences from that manufactured set of six could be delivered. These could be selected to maximize epitope matches and minimize mismatches between the vaccine and the within-host viral quaisispecies.
One of the outputs of the Epigraph tool suite (http://www.hiv.
lanl.gov/content/sequence/EPIGRAPH/epigraph.html) is a count of each unique potential epitope (9-mer) in a dataset
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; this is the fundamental information that forms the basis of the nodes in the graph, and it is useful for identifying conserved regions from the perspective of epitope length fragments. This count is also informative in that it provides a more immunologically relevant, albeit more sobering, lens with which to view HIV-1 diversity compared to a standard phylogeny 
| Combining conserved region and polyvalent approaches
A third area of interest for HIV-1 T-cell vaccine design is the idea of focusing responses on epitopes that are presumed to be beneficial because they are either highly conserved, [49] [50] [51] [52] 34 In a recent mosaic vaccine described by Ondondo et al.
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, included regions were restricted not only by being the most conserved regions, but were further limited to include only regions that spanned epitopes that were deemed protective, in that responses to these epitopes were associated with low viral loads in natural infections. 54 Indeed, it was found that infected people with enriched responses to epitopes embedded in the secondgeneration conserved region vaccine had lower viral loads, supporting the utility of the strategy of immune response focusing. 
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, and the V3g bNAbs (eg, PGT128) which generally target an N-linked glycan at position 332, eg, Kong et al.
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Because of the cross-reactive potential of bNAbs, their epitopes are often described as conserved. This is an important distinction in outlook, because it directly impacts the priorities for vaccine design. If, as we propose, the exposure of B-cell lineages to viral mutations that confer relative resistance is necessary to select for antibodies able to overcome that resistance, then it follows that polyvalent vaccines representing immunologically relevant epitope diversity may be essential to achieve breadth and potency. This hypothesis is supported by the in vivo development of antibody breadth, as it has been traced over years in infected subjects who are followed over time. 11, 13, 68, 69 The B-cell lineages that eventually produce bNAbs indeed start out with limited or no heterologous neutralization breadth, but can bind the autologous virus that stimulated them. These interactions eventually drive selection of epitope variants. Importantly, epitope diversification arises in vivo prior to the development of heterologous breadth and concurrent with expansion of autologous breadth 11, 13, [68] [69] [70] (also M. Bonsignori and B.F. Haynes, unpublished data). These observations, plus the general observation that serum neutralization breadth is overall slow to develop during human infection 71 (see Figure 3 for an example), supports the premise that exposure to epitope diversity may be an essential aspect of the evolution of antibody breadth in vivo.
One polyvalent vaccine design strategy that derives from these observations is a lineage-based design, 21 68 and it is possible that particular Envs have a propensity to bind to these germ-line B-cells. The choices of prime and successive boost Env immunogens using the lineage-based design approach are illustrated below using the data from the subject CH505, who developed CD4bs bNAbs.
In contrast to an affinity-based B-cell lineage-design strategy, it will also be important to test the hypothesis that exposure to com- 76 Non-neutralizing antibodies can limit the number of viruses in passive protection studies. 77 The challenge of contending with HIV-1 diversity remains, regardless of the functionalities that protective antibodies employ. Some of the approaches outlined here could also be applied to developing vaccines that target other antibody functionalities.
| IMMUNE SELECTION IN LONGITUDINAL SAMPLES: ONTOGENY OF CD4BS BNABS IN SUBJECT CH505
As summarized above, one approach for vaccine development is to recapitulate key events in bNAb induction that have actually occurred in a specific HIV-1 infected individual who made particularly good bNAb response. A case in point is the study of subject CH505, for whom Env-antibody coevolution was chronicled starting at the time of acute infection. neutralization and binding sensitivity were tested against panels of autologous and heterologous Envs. 11 The gains and losses in binding affinity and neutralization during bNAb ontogeny were evaluated, point mutations and insertions in Env were identified that were associated with neutralization escape, and the viral diversification was characterized as the viral quasispecies evolved in response to immune selection. 11, 67 CH103 maturation was initially facilitated by escape mutants, which were selected by early antibodies in the cooperating CH235 lineage 13, 68 ( Figure 4 ). Unlike CH103, CH235 is a CD4 mimic, similar to the VRC01-class of CD4bs bNAbs. 
| From quasispecies to swarms
Longitudinal studies of Env-antibody coevolution such as those undertaken for CH505 involve sequencing hundreds to thousands of Env variants from one subject. It is, however, feasible to test binding and neutralization for only a fraction of these. We therefore Deeper reds indicate higher affinity, gray undetected. Each row in this figure follows the ordering of leaves in the tree on the right (C), which was made by maximum likelihood (in phyML, with HIVw+g4+I) from gp120 sequences. The CH505 TF sequence was used to root the tree. Note that these sequences were selected for experimental evaluation prior to the availability of LASSIE. d0000 w000  d0028 w004  d0099 w014  d0141 w020  d0211 w030  d0371 w053  d0547 w078  d0701 w100  d0953 w136  d1121 w160 ELISA binding log AUC, gp120 
single-genome-amplification (SGA) derived Envs that were sampled over a period spanning the first 3 years of infection. These sites corresponded to verified immune targets in this donor. The algorithm next identified 54 Envs that represent all recurrent mutations in the 35 selected sites in CH505. Importantly, an Env was selected to represent each of these mutations as they initially occurred, so that each mutation of interest was represented in the 54 Env set in the context of the natural Env where it was first observed. These variants are more likely to display an immunologically natural phenotype, compared to, for example, an out-of-context mutation introduced into the TF virus by site-directed mutagenesis. The 54 Envs were well-dispersed throughout the CH505 phylogeny, and represented the development of antibody binding and neutralization observed in a larger set of previously studied handpicked Envs 11,13,74 ( Figure 4) . The LASSIE algorithm chooses sequence sets with more recurrent mutations represented, and less redundancy, than random or "by hand" selection. 74 Thus, the algorithm objectively provides a minimal, manageable number of Envs to represent diversity in natural infection, to aid in the study virus-antibody coevolution. We call this minimal representation of antigenic diversity an "antigen swarm."
We initially developed LASSIE to explore mutational patterns in vivo and for reagent design in longitudinal studies. However, given the emergence of new vaccine technologies that may enable the use of high valency antigen cocktails, this approach could also be used to design a vaccine that mimics viral evolution in an individual who made potent bNAb responses. that greater diversity in a vaccine will be important, or necessary, for the development of heterologous neutralization breadth. Therefore, our group is beginning to explore ways to deliver larger sets of Envs as an alternative vaccine strategy. . One way to achieve such exposure through vaccination might be through a lineage-based design that is followed by a mosaic boost. This possibility is addressed in an example below, from subject CH848.
| Swarm immunogen delivery
There are serious technical and regulatory challenges associated with delivery of a highly multivalent vaccine; still the concepts may merit exploration in animal models. DNA administration, which exploits host cellular processes for antigen expression, [78] [79] [80] is the simplest approach that may be feasible. In addition to administration of naked DNA with electroporation, several biotechnology alternatives exist as DNA vaccine delivery methods, and new technologies continue to offer promise. [81] [82] [83] [84] Another unresolved question is how best to deliver such a complex set of antigens. Figure 5B illustrates two alternatives for increasing immunogen diversity using serial boosts, again using CH505 as an example. We would start with a prime intended to trigger appropriate B-cell lineages. In the case of CH505, this prime would include three Envs, starting with the TF and two mutant
Envs that bound with high affinity to the unmutated ancestors of the CH103 and CH235 lineages. 68 We would divide the swarm of 54 Envs into three different groups of boost immunogens, including 18 Envs each (a, b, and c). These groups gradually increase sequence diversity among sites known to be associated with immune escape in CH505.
Envs in group a are the set sampled earliest in infection, and have the fewest mutations relative to the CH505 TF. Groups b and c have progressively greater levels of diversity and later sampling times. These sets could either be administered either sequentially (a, followed by b alone, and finally c alone) or cumulatively (a, followed by a and b, then finally a and b together with c) ( Figure 5B ).
| V3 GLYCAN BNAB ONTOGENY IN SUBJECT CH848: LINEAGE PLUS DIVERSITY DESIGN
Another roadmap for lineage-based vaccine development was the ontogeny of bNAbs in subject CH848, who was infected by a single clade C TF virus. CH848, like CH505, was followed from early infection for many years, spanning the period when broadly neutralizing antibodies against heterologous strains began to develop roughly 3.5 years into The CH848/DH270 lineage-based design includes a new feature relative to CH505. Changes in the hypervariable V1 region of Env appeared to be critical in the ontogeny the DH270 in subject CH848.
The TF virus in CH848 had an atypically long V1 loop; the two cooperating lineages, DH272 and DH475, bound and neutralized the TF and other early CH848 viruses that carried this long V1. Shorter V1s
were selected, as they conferred resistance to one of these early cooperating antibodies. In contrast, the earliest antibodies of the DH270 lineage, which we hope to emulate with a vaccine, targeted only Envs with short V1 loops, and the DH270 B-cell lineage was not triggered until viruses with short V1 loops dominated the CH848 quasispecies.
After the DH270 lineage was initiated, longer V1 loops began to be replenished in the viral quasispecies; these were more resistant to early Korber, P. Hraber, and B. Haynes, unpublished).
| Augmented vaccine compositions
If lineage-based design strategies as exemplified by those described for CH848 (M. Bonsignori and B. Haynes, personal communication) and CH505 68, 74 above can indeed trigger B-cell lineages that initiate heterologous breadth at the population level, they may also benefit from a boost with a mosaic vaccine, comprised of three antigens designed to best capture variation in linear epitopes at the population level. 36 A case for this is made in Figure 6 . Some residues in the PGT128 contact surface (thought to be similar to DH270.6 contacts) that are shown in Figure 2 are quite variable. DH270.6 was the best antibody within the DH270 lineage in terms of breadth and potency, but still it only neutralized 55% of M group viruses tested. Moreover, DH270 bNAbs never acquired the very high potency that is observed for some of the other V3 glycan bNAbs. 61 We hypothesize that this may be in part because the CH848 viruses carry some non-consensus rare amino acids near the contact surface of DH270 antibodies. It is possible that, in spite of the CH848 viral quasispecies selecting for antibodies that are able to interact with many heterologous Envs, the rare CH848-specific Env substitutions may have a negative impact, limiting affinity and breadth of DH270 antibodies at the population level. The enhanced coverage of heterologous viral variation afforded by augmenting lineage-based design with a mosaic boost is F I G U R E 6 Structural mapping of global sequence coverage at V3 glycan bNAb contact sites by candidate vaccine immunogens. Positionwise sequence coverage is calculated as the percentage of sequences in a commonly used 207 M-group virus neutralization panel that have the same amino acid as at least one of the sequences for a given vaccine strategy. Vaccine strategies considered are: Con-S, an M group consensus; the CH848 is a 5-valent CH848/DH270 lineage-based design, and a 3 valent Env mosaic. 36 Con S and the mosaic Envs are currently being evaluated in the HVTN106 Phase I human trial. Color-coding for sequence coverage is indicated by the color bar, with red shades indicating low, yellow indicating intermediate and blue indicating high sequence coverage. Crystal structure for a subtype G Env SOSIP trimer 60 (PDB:5FYJ) was used, and PGT128 contacts from Figure 2 are used. This figure shows a close-up view of the PGT128 contacts as in Figure 1B summarized in Figure 6 . While a pentavalent CH848/DH270 lineagebased design does a better job of covering V3 glycan epitope amino acid diversity than a single M group consensus, the lineage-based designed complemented by a mosaic boost would do better still.
A similar story is found for the CH505 Env quasispecies which has its own set of quirks, ie, unusual amino acids in the CD4 binding region ( Figure 5 ). Again a mosaic boost might shift vaccine-elicited antibody recognition toward improved heterologous breadth and potency. Because mosaics by definition carry common and complementary variants, we propose that they could be used generally to augment any lineagebased design, by including the more common forms of an epitope that are missing from the viral quasispecies isolated from a single individual.
This kind of mosaic coverage of the most common variants would be throughout Env, and analogous to the V3 glycan example shown here, could also potentially support breadth in any antibody target region.
| CONCLUSIONS AND FUTURE PERSPECTIVES
HIV/AIDS has become a manageable disease with respect to therapy, but the need to curb viral transmission through a vaccine remains a high and urgent priority. Fortunately, significant advances have been made in recent years, giving ample reason for hope that the challenges are not insurmountable. Overcoming viral diversity, the primary focus of this review, is a major issue, but many additional challenges will need to be addressed before a vaccine can be successful. For example, the bNAbs that arise during natural HIV-1 infections tend to have unusual features likely to pose challenges for vaccination, such as high levels of somatic mutation, autoreactivity with self proteins, and long complementarity determining regions. 21 Progress has been made on many fronts that may help us deal with these and other unresolved issues. For antibody induction, advances have been made in terms of better understanding of the structure of the native Env trimer and the role of the glycan shield in antibody interactions. 60 More native-like forms of the Env trimer for vaccine delivery are being explored. 85, 86 Novel safe ways to modulate immune tolerance and enable vaccine induction of polyreactive and autoreactive antibodies are also being explored. 87 For cytotoxic T lymphocyte (CTL) focused vaccines, new delivery approaches are being used, 33, 88 and preclinical testing of conserved region polyvalent mosaics vaccines is underway. 51 A desirable long-term goal may be to merge parallel B-cell and T-cell focused vaccine strategies into an immunological "one-two punch". This combined approach would incorporate vaccine elements that enable elicitation of antibodies that effectively block infection, coupled with elements that elicit favorable T-cell responses to provide immune-mediated control of breakthrough infections. Inclusion of diversity considerations, as outlined here, may contribute in important ways to this success.
